Reading view

AI-enhanced adaptive virtual screening of large libraries for ligand discovery

Nature Biotechnology - Issue - nature.com science feeds

By: Domiziana Cecchini · AkshatKumar Nigam · Ming Tang · Joana Reis · Matt Koop · Andrea Gottinger · Callum Robert Nicoll · Yao Wang · Abhilash Jayaraj · Süleyman Selim Çınaroglu˘ · Ricarda Törner · Yehor Malets · Minko Gehev · Krishna M. Padmanabha Das · Kelly Churion · Jongwan Kim · Nidhin Thomas · Yong Li · Hyuk-Soo Seo · Sirano Dhe-Paganon · Christopher Secker · Mohammad Haddadnia · Alexander Hasson · Minkai Li · Abhishek Kumar · Roni Levin-Konigsberg · Eun-Bee Choi · Geoffrey I. Shapiro · Huel Cox 3rd · Luke Sebastian · Chelsea Braithwaite · Puspalata Bashyal · Dmytro S. Radchenko · Aditya Kumar · Lei Yang · Pierre-Yves Aquilanti · Henry Gabb · Amr Alhossary · Eric O’Neill · Gerhard Wagner · Alán Aspuru-Guzik · Yurii S. Moroz · Charalampos G. Kalodimos · Konstantin Fackeldey · John D. Schuetz · Andrea Mattevi · Haribabu Arthanari · Christoph Gorgulla

1 September 2026 at 08:00

Nature Biotechnology, Published online: 01 September 2026; doi:10.1038/s41587-026-03217-x

Massive chemical libraries are screened computationally at scale.

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

Nature Medicine

By: Priscilla Merriam · James J. Morrow · Emanuele Mazzola · Nicole L. Solimini · Prafulla C. Gokhale · Ping Chi · Alice P. Chen · Mark Agulnik · Melissa Burgess · Scott M. Schuetze · Neeta Somaiah · Brian A. Van Tine · Seth M. Pollack · Gabriel Tinoco · Jonathan Trent · Breelyn A. Wilky · Nicola Bothwick · Benjamin K. Eschle · Vivian Nguyen · Jan H. Beumer · Noushin Rastkari · Shahanawaz Jiwani · Peter I-Fan Wu · Lorraine Pelosof · Matthew L. Hemming · Geoffrey I. Shapiro · George Demetri · Bradley Bernstein · Suzanne George

26 May 2026 at 08:00

Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04376-9

In a multicenter phase 2 trial, the fibroblast growth factor receptor inhibitor rogaratinib showed encouraging clinical efficacy in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors, suggesting a potential new treatment option for this patient population and demonstrating that an epigenetic mechanism of oncogene activation can be successfully targeted with a tyrosine kinase inhibitor.